SignalXSignalX

INVA Innoviva, Inc.

Q3 2025 10-Q
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Innoviva, Inc. Overview

Innoviva, Inc. (INVA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New operational risk: FDA Priority Review of zoliflodacin with PDUFA date Dec 15, 2025, no advisory committee meeting planned (triggered by NDA acceptance in June 2025)
  • • Most materially updated financial risk: Convertible noteholders converted $192.5M principal to 11.1M shares in Aug 2025, reducing debt and interest expense
+3 more insights

Get deeper insights on Innoviva, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.